期刊文献+

不同剂量阿托伐他汀对冠心病患者的疗效和安全性多中心研究 被引量:21

原文传递
导出
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2005年第12期1085-1087,共3页 Chinese Journal of Cardiology
  • 相关文献

参考文献7

  • 1方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 2全国高胆固醇血症控制状况多中心研究协作组.高胆固醇血症临床控制状况多中心协作研究——达标率及影响因素[J].中华心血管病杂志,2002,30(2):109-114. 被引量:176
  • 3Pearson TA,Laurorol I,Chu H,et al.The lipid treatment assessment project (L-TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Arch Intern Med,2000,160:459-467. 被引量:1
  • 4李建勇,胡大一,仝其广,史旭波,吴明营,陈捷.中国医师血脂异常防治知识调查[J].中华内科杂志,2005,44(6):461-463. 被引量:23
  • 5Jones PH,McKenney JM,Karalis DG,et al.Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients withdyslipidemia.Am Heart J,2005,149:1-8. 被引量:1
  • 6Law MR,Wald NJ,Rudnicka AR.Quantifying effect of statins on low density lipoprotein cholesterol,ischaemic heart disease,and stroke:systematic review and meta-analysis.BMJ,2003,326:1423-1429. 被引量:1
  • 7Pasternak RC,Smith SC Jr,Bairey-Merz CN,et al.ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.Circulation,2002,106:1024-1028. 被引量:1

二级参考文献16

  • 1Slamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol a nd risk of premature death from coronary heart disease continuous and graded ? F indings in 356,222 primary screenees of the Multiple Risk Factor Intervention Tr ial (MRFIT). JAMA, 1986,256:2823-2828. 被引量:1
  • 2Castelli WP, Garrison RJ,Wilson PwF, et al. Incidence of coronary heart disea se and lipoprotein cholesterol levels: the Framing ham Study. JAMA, 1986, 256:28 35-2838. 被引量:1
  • 3Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S).Lancet,1994,344:1383 -1389. 被引量:1
  • 4Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary- prevention t ri al with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment ,c hages in risk factors, and incidence of coronary heart disease. N Engl J Med, 1 987,317:1237-1245. 被引量:1
  • 5Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease wit h pravastatin in men with hypercholesterolemia. West of Scotland Coronary Preven tion Study Group. N Engl J Med,1995,333:1301-1307. 被引量:1
  • 6Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary e v ents with lovastatin in men and women with average cholesterol levels: results o f AFCAPS/TexCAPS. Air Force/Texas Coronary Artherosclerosis Prevention Study. JAMA .1998;279:1615-1622. 被引量:1
  • 7Summary of the second report of the National Cholesterol Education Program (NC EP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholestero l in Adults ( Adult Treatment Panel II Report). JAMA, 1993, 269:3015-3023. 被引量:1
  • 8Report of the National Cholesterol Education Program Expert Panel on Detection , Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Pan el. Arch Intern Med, 1998, 148:36-69. 被引量:1
  • 90 Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L -TAP):a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choles terol goals. Arch Intern Med, 2000, 160:459-467. 被引量:1
  • 10Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 subjects with coronary heart disease: The Scandinavian Simvastatin Survival Study(4S). Lancet,1994,344:1383-1389. 被引量:1

共引文献3202

同被引文献313

引证文献21

二级引证文献139

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部